论文部分内容阅读
目的：为研究表皮生长因子受体（ＥＧＦＲ）与卵巢癌发生发展的关系。方法：采用ＡＢＣ免疫组化、原位杂交方法研究了ＥＧＦＲ在６０例卵巢肿瘤（包括３８例卵巢癌，１０例良性卵巢肿瘤，１２例交界性卵巢肿瘤）及１２例正常卵巢组织中的表达。结果：ＥＧＦＲ在卵巢癌、良性卵巢肿瘤、交界性肿瘤及正常卵巢组织四组中的免疫组化检出率分别为７６．３２％、４０％、６６．６７％和４１．６７％，除交界性肿瘤组外，后三组与卵巢癌组相比差异显著（Ｐ＜０．０５）。原位杂交结果显示ＥＧＦＲｍＲＮＡ在各组中的表达率分别为６５．７９％、２０．００％、３３．３３％和２５．００％，后三者与卵巢癌组间有显著差异（Ｐ＜０．０５）。结论：ＥＧＦＲ在卵巢癌中有较高水平的表达，表明ＥＧＦＲ在卵巢癌的发生发展中起着重要的作用。
Objective: To study the relationship between epidermal growth factor receptor (EGFR) and the development of ovarian cancer. METHODS: The expression of EGFR in 60 ovarian tumors (including 38 ovarian cancers, 10 benign ovarian tumors, 12 borderline ovarian tumors) and 12 normal ovarian tissues was studied using ABC immunohistochemistry and in situ hybridization. Results: The immunohistochemical detection rates of EGFR in ovarian cancer, benign ovarian tumor, borderline tumor and normal ovarian tissue were 76.32%, 40%, 66.67% and 41.67%, respectively. Outside the tumor group, the difference between the latter three groups and the ovarian cancer group was significant (P<0.05). The results of in situ hybridization showed that the expression rates of EGFR mRNA in each group were 65.79%, 20.00%, 33.33%, and 25.00%, respectively. There was a significant difference between the latter three groups and the ovarian cancer group (P<0). .05). Conclusion: EGFR is highly expressed in ovarian cancer, indicating that EGFR plays an important role in the development of ovarian cancer.